Consecutive blood letting and peginterferon alfa-2a/ribavirin standard treatment compared to peginterferon alfa-2a/ribavirin standard treatment alone for treatment-naive patients with hepatitis C virus genotype one and elevated ferritin levels.
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2011
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms KAPRI
- 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 30 Jun 2009 Primary endpoint 'Viral-kinetic-parameters' has not been met.
- 30 Jun 2009 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History